Radiance Therapeutics is a compelling opportunity to enter the growing ophthalmic device market with a lead technology. Glaucoma is the leading cause of irreversible blindness worldwide. Recognized by the ophthalmic community as a critical unmet need, current standard of care glaucoma drainage surgery fails in 50% of patients, leading to irreversible blindness. RadianceTx is commercializing a proprietary medical device to address this unacceptably high failure rate. Utilising beta therapy, clinically proven in randomised controlled trials to significantly improve outcomes with a 90% success rate, this disruptive technology has the potential to revolutionize the treatment of glaucoma and save patients from blindness.